Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Marla the CEO stated that going forward the company will flesh out the numbers on the deals signed to date.
Just using the Endorsements from the two Medical Bodies that have agreed to promote the Trellus App covers the 3,000,000 sufferrers of Irittable Bowel Disease in the U.S.
If only 5% of sufferers use the app that's 150,000 patients and the company break even is 7,000.
The app has already shown that users are significantly less likely to require serious medical intervention of steroids, opioids and surgery with users reporting significant improvements in their mental well being and lifestyle.
This doesnt include the new IBS variant of the app which is due to launch and other world markets.
2 of America's biggest health cover providers are looking at it as their costs for sufferers of poorlifestyle management and non adherence to medical treatments cost them Billions per year.
3 contracts signed in New York state already, assuming even distribution of sufferers per state its circa 60,000 patients per state but New York will be higher than Nebraska say, could they already be at 7,000 patients signed up with the New York contracts?
Just reviewed the Presentation
total Market in the USA ( Canada has been given approval as well) 33,000,000 in Both Irritable Bowel Diseases and Irritable Bowel Syndrom- break even for the company 7,000 patients or 0.021% of the market!!!!
Contracts signed
Crohns and Collitis Foundation- exclusive deal to offer the App via the Foundation's website and endorsed by the Foundation
Exclusive Deal with the American College of Gastroenterologists to offer the app through the 16,000 Pratitioners of the college to their patients.
2 of the largest Health Insurance providers in final stage discussions to provide the app to their members with GI conditions.
Approached by Large Pharma to assist in running Phase 2 and Phase 3 trials for GI medication.
Mount Sinai Hospital signed up to provide the app to its Staff.
New Yor Medicaid provider contract signed.
New York labour Union signed up to provide App to its members with GI conditions.
Targeting 50% market share!!!!
Double digits first would be nice, still not even equal to cash position, utter lunacy, that presentation needs to be diseminated to a wider audience. They all expressed their dismay at the share price, it wont realise its potential without some drum banging, hopefully one or two of those big pharma and insurance company deals gets RNSd soon. 65p all time high this year shows whats possible.
Tivman,
it was agood watch, by virtue of Marla's profffessional standing shes basically made the App available to 100% of the market via the two main proffesssional Gastrointestinal Bodies in the USA, which are endorsing it for people with GI conditions, you can see the big medical insurance companies pushing this hard as it will reduce their outlays significantly for reactive medical treatments and procedures. Might not get insured unless you agree to follow the app protocols going forward.
Enjoy it Mike.
Very Impressive, so undervalued, endorsed by the two most significant Gastro Intestinal Medical bodies in the US with exclusive agreements to help their memebers and doctors with big contracts coming on line. Only need a tiny fraction of the addressable market to break even. The two Gastro Intestinal organisations will access all of the adressable market.
· The final group of subjects completed dosing on 30 March 2022. This was a group of subjects that received an intravenous injection of a 800 mcg dose of P140, which showed successful measurement of the absolute bioavailability of the drug (as a control)
· Importantly, and in-line with all human dosing to date, P140 was safe and well tolerated across all doses and in all subjects
· This positive PK data now clears the path for commencement of all clinical studies within the P140 platform. In addition to lupus, there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy ("CIDP")
· Avion Pharmaceuticals, our US partner, has been integral to the development, initiation and successful conclusion of this PK study. Together, we are preparing next steps for the progression of the P140 clinical program and this will be communicated in due course.
So do you think another phase 2 trial is required?
There was a clear implication that by following the guidance regulatory approval would follow, now that is significant in my view. So faced with a potential billion dollar revenue stream and as good a road map as you are likely to get, do you throw your cards in or incorporate the changes.